Elaine Mary Shannon Sells 3,978 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Elaine Mary Shannon sold 3,978 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $68,023.80. Following the completion of the transaction, the insider directly owned 63,333 shares of the company’s stock, valued at approximately $1,082,994.30. This trade represents a 5.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.0%

Takeda Pharmaceutical stock opened at $17.41 on Friday. The firm has a 50 day simple moving average of $16.53 and a 200 day simple moving average of $17.14. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90. The firm has a market capitalization of $55.77 billion, a price-to-earnings ratio of 51.19 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $6.90 billion for the quarter. On average, analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Takeda Pharmaceutical News Roundup

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
• Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
• Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
• Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing

Institutional Investors Weigh In On Takeda Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after acquiring an additional 370,800 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Takeda Pharmaceutical in the fourth quarter valued at $998,000. Quantinno Capital Management LP raised its position in Takeda Pharmaceutical by 20.6% during the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares in the last quarter. Bleakley Financial Group LLC raised its position in Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock valued at $7,993,000 after purchasing an additional 68,844 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Takeda Pharmaceutical during the second quarter worth about $351,000. Institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TAK. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.